3[3]Garcia-casado N,Nmalumbres Chararren I,Torres Sancho C,et al.Post-operative care for heart transplant patients.Review of the last 2 years[J].Enferm Intensiva,1998,9(1):3-9.
10[10]Abbott KC,Hypolite I,Poropatich RK,et al.Hosp-italizations for fungal infections after renal transplantation in the United Statesl Transplant[J].Infect Dis,2001,3(4):203-211.
6Nashan B, Light S, Hardie IR, et al, Reduction of acute renal allograft rejection by daclizumab. Transplantation, 1999,67 : 110.
7Kandus A, Grego K, Bren A, et al. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Ther Apher Dial ,2005,9 (3) : 262.
8Dharnidharka VR, Araya CE. Post-transplant lymphoproliferafive disease. Pediatr Nephrol,2009,24(4) :731.
9McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineufin inhibitor, sirolimus and steroids. Am J Transplant, 2008,8(5) :984.
10Crompton JA, Somerville T, Smith L, et al. Lack of economic benefit with basiliximab induction in |iv/ng related donor adult renal transplant recipients. Pharmacotherapy ,2003,23 (4) :443.
